Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus

Assiut University

Status: Unknown

Conditions: Systemic Lupus Erythematosus

Treatments: Diagnostic Test: Ribosomal p2 Autoantibodies as a Serum marker

Study type: Observational

Funder types: Other

Identifiers

NCT05179018

Rib P2 antibodies in sle pts

Details and patient eligibility

About

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by production of autoantibodies directed against nuclear and cytoplasmic antigens. Clinically, this disorder is characterized by periods of remission and relapse (1). The early and accurate diagnosis of SLE is challenging (2).

The SLE pathogenesis involves multiple cellular components of the innate and immune systems, presence of autoantibodies and immune complexes, engagement of the complement system and cytokine dysregulation (3). About 180 autoantibodies have been identified in SLE patients, 102 of which are reported to have an organ-specific correlation with SLE disease identified in SLE patients, with SLE disease activity (4). However, with the exception of autoantibodies such as antinuclear antibody (ANA), anti double stranded DNA (dsDNA), anti-smith and antiphospholipid antibodies, currently proposed by the American college of rheumatology (ACR) (5)

Full description

systemic lupus international collaborating clinics (SLICC) (6) for the diagnosis of SLE, most of these autoantibodies lack sufficient sensitivity and/or specificity for use in clinical diagnosis. Discovery of additional autoantibodies with high sensitivity and specificity is important for early diagnosis and assessment of the prognosis of SLE (7).

Anti-ribosomal P(Anti-Rib-P) antibody, routinely tested in SLE, targets a homologous 22-amino acid C-terminal (C-22) sequence shared by three ribosomal phosphoproteins known as P0, P1, and P2 (8).

The prevalence of anti-Rib-P antibody is about 15-40% in SLE patients and varies with the ethnicity, disease activity and detection method (9). Studies have disclosed that anti-P antibodies react with activated T cells but not with B cells, suggesting possible direct effects of anti-P antibodies on immune regulation (10).

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients who fulfilled the 2012 SLICC criteria (6).
2. SLE Patients >= 18 years old.

Exclusion criteria

• 1-SLE Patients < 18 years old. 2- Patients with other autoimmune diseases or malignancy.

Trial design

90 participants in 2 patient groups

SLE patients group

Description:

The study will include 50 patients suffering from SLE, all patients with SLE should fulfill 2012 SLICC criteria

Treatment:

Diagnostic Test: Ribosomal p2 Autoantibodies as a Serum marker

Healthy control group

Description:

Control group of 40 healthy volunteers with age and gender-matched with SLE patients.

Treatment:

Diagnostic Test: Ribosomal p2 Autoantibodies as a Serum marker